Part I — The story
The story
Kiran Mazumdar-Shaw trained as a brewer — unable to find a brewmaster job in 1970s India because of her gender — and instead founded Biocon in 1978 from a garage with a tiny sum, initially making industrial enzymes. Facing barriers at every turn as a woman entrepreneur in a field that barely existed in India, with little access to capital or skilled talent, she built Biocon into the country's largest biopharmaceutical company and a global player in affordable medicines.
Mazumdar-Shaw's strategic bet was on affordable innovation: using India's cost advantages to develop and manufacture biosimilars and insulin for the price-sensitive markets of the developing world, making advanced medicines accessible to millions who could never afford Western prices. She is a study in persistence against systemic barriers, in building an industry where none existed, and in the strategy of affordable innovation — serving vast underserved markets that the incumbents' pricing ignored.
Part II — The playbook
The playbook
Persist against systemic barriers
Shut out as a brewer, Mazumdar-Shaw built a biotech company instead.
Pursue affordable innovation
She used cost advantages to make advanced medicines affordable to millions.
Build the industry you need
She created biotech capability where India had almost none.
In their words
If you have the self-belief, then nothing can stop you.
I want to be remembered for making a difference, not for making money.
Affordable innovation is the need of our times.
What to read next
- Kiran Mazumdar-Shaw (business profiles) —
Why this matters
The thinking behind these decisions connects to models you can study directly:
Frequently asked questions
How did Kiran Mazumdar-Shaw start Biocon?
Unable to find a brewmaster job in 1970s India because of her gender, she founded Biocon in 1978 from a garage making industrial enzymes — and built it into India's largest biopharmaceutical company.
What is Biocon's strategy?
Affordable innovation — using India's cost advantages to develop and make biosimilars and insulin for the developing world, making advanced medicines accessible to millions who couldn't afford Western prices.